Glioblastoma Drug Treatment Study

Clinical Trial Title

A phase II/III randomized trial of veliparib or placebo In combination with adjuvant temozolomide In newly diagnosed glioblastoma with MGMT promoter hypermethylation.

Clinical Trial Protocol Description:

This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a newly diagnosed glioblastoma or gliosarcoma.
  • Have completed temozolomide (TMZ) therapy with radiation.
  • Have had no chemotherapy, immunotherapy, or radiation therapy other than temozolomide (TMZ) therapy with radiation.
  • Are at least 18 years of age.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Clement Pillainayagam, MD

Contact Information

Rush Cancer Center Clinical Trials Office